Document text
Principal Investigator: FRED R HIRSCH
Organization: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Fiscal Year: 2024
Award: $119,921
Funding agency: National Cancer Institute
ADMINISTRATIVE CORE: ABSTRACT
Our inter-institutional U54 Serological Sciences Center of Excellence (“U54”) Administrative Core
provides scientific and administrative oversight for all of the U54’s Projects and Cores. It also provides the main
interface with patient advocates, NCI program staff, external and internal advisory boards, NCI SeroNet activities,
other Lung Cancer NCI Networks, and collaborating institutions. The Center’s Administrative Core is led by three
world leaders in lung cancer translational research, founders of the COVID-19 Lung Cancer Consortium (CLCC),
who all have extensive experience leading large and complex lung cancer translational research programs: Dr.
Fred R. Hirsch at the Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, Dr. John Minna at
UTSW and Dr. Paul A. Bunn Jr. at the University of Colorado. The Administration Core PIs will work closely with
the U54 overall Co-PI (Dr. Adolfo Garcia-Sastre), the U54’s Steering Committee, which consists of the overall
PIs, the Administrative Core PIs, the Project and Core PIs, and a representative for our partner organization, the
patient advocacy organization GO2 Foundation for Lung Cancer. The U54’s Steering Committee will have the
assistance and advice of an Internal Advisory Board (IAB) and an External Advisory Board (EAB). The IAB
will be established within the Mount Sinai Health System and will provide scientific advice and smooth access to
required institutional resources. The EAB consists of international leaders in thoracic oncology and in medical
virology and vaccinology and will assist with providing scientific advice and evaluating scientific progress with a
special focus on lung cancer implications. The specific aims of the Administrative Core are: AIM 1: Direct
the overall scientific integration and administrative management of the U54 and ensure effective communication
between U54 Project and Core investigators; AIM 2: Oversee Administration of Patient Cohorts, Clinical Studies,
Financial Reporting, and Regulatory Aspects; and AIM 3: Manage connection of the U54 with the NCI, SeroNet,
and other lung cancer research (e.g. NCI Lung-SPORE) and patient advocacy networks. Thus, the
Administrative Core will help this U54 to maximize its potential both internally (Mount Sinai, UTSW, and
University of Colorado), and inter-institutionally, including interactions with the NCI Serological Sciences Network
and the Frederick National Laboratory for Cancer Research (FNLCR).
Successful completion of our U54 activities is expected to substantially increase our understanding of the
association between lung cancer SARS-CoV-2 antibody response based on infection or vaccination, and
ultimately be of significant service in designing lung cancer patient-specific SARS-CoV-2 preventive measures.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Adherence><Administrative Management><Administrator><Advocate><Age><Antibodies><Antibody Response><Area><Basic Research><Basic Science><Budgets><COVID-19><COVID-19 antibody><COVID-19 infection><COVID-19 predisposition><COVID-19 susceptibility><COVID-19 virus><COVID-19 virus infection><COVID-19 vulnerability><COVID19 infection><COVID19 virus><CV-19><Cancer Center><Cancer Patient><Cancers><Care Givers><Caregivers><Clinical><Clinical Research><Clinical Study><CoV-2><CoV2><Collaborations><Colorado><Communication><Complex><Consult><Coronavirus Infectious Disease 2019><Coronavirus disease 2019 predisposition><Coronavirus disease 2019 susceptibility><Coronavirus disease 2019 vulnerability><Data Science Core><Data Science Resource Core><Doctor of Medicine><Doctor of Philosophy><Ensure><Epidemiology><Expenditure><Foundations><Gender><Health system><Hearing><Infection><Institution><Interdisciplinary Research><Interdisciplinary Study><International><Investigators><Laboratories><Leadership><Lung><Lung Respiratory System><M.D.><Malignant Neoplasms><Malignant Thoracic Neoplasm><Malignant Thoracic Tumor><Malignant Tumor><Malignant Tumor of the Lung><Malignant Tumor of the Thorax><Malignant neoplasm of lung><Malignant neoplasm of thorax><Medical><Monitor><Multidisciplinary Collaboration><Multidisciplinary Research><NCAB><NCI Organization><National Cancer Advisory Board><National Cancer Institute><Office of Administrative Management><Patient Recruitments><Patient advocacy><Patients><Ph.D.><PhD><Predisposed to COVID-19><Predisposed to SARS-CoV-2><Predisposed to Severe acute respiratory syndrome coronavirus 2><Preparation><Preventative measure><Preventive measure><Principal Investigator><Progress Reports><Publications><Pulmonary Cancer><Pulmonary malignant Neoplasm><Reporting><Research><Research Activity><Research Personnel><Research Resources><Researchers><Resource Sharing><Resources><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 infection><SARS-CoV-2 predisposition><SARS-CoV-2 susceptibility><SARS-CoV-2 vulnerability><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Science><Scientific Publication><Serology><Services><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 predisposition><Severe acute respiratory syndrome coronavirus 2 susceptibility><Severe acute respiratory syndrome coronavirus 2 vulnerability><Severe acute respiratory syndrome related corona virus 2><Socio-economic status><Socioeconomic Status><Texas><Thoracic Oncology><Translational Research Enterprise><Travel><Universities><Vaccination><Vaccines><Voice><Work><Wuhan coronavirus><advocacy organizations><ages><anti-cancer research><antibody against COVID-19><antibody against SARS-CoV-2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><cancer research><cohort><conference><consults><convention><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 infection><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus infectious disease-19><data sharing><design><designing><distinguished professor><epidemiologic><epidemiological><ethnic diversity><ethnically diverse><experience><hCoV19><human subject><individual responsibility><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inter-institutional><lung cancer><malignancy><medical college><medical schools><meeting><meetings><nCoV2><neoplasm/cancer><participant recruitment><predisposed to Coronavirus disease 2019><preparations><professor><programs><pulmonary><recruit><school of medicine><severe acute respiratory syndrome coronavirus 2 antibody><socio-economic position><socioeconomic position><summit><susceptible to COVID-19><susceptible to Coronavirus disease 2019><susceptible to SARS-CoV-2><susceptible to Severe acute respiratory syndrome coronavirus 2><symposia><symposium><synergism><thoracic cancer><thoracic malignancies><timeline><translation research enterprise><translational cancer research><translational research program><vaccinology><virology><vulnerable to COVID-19><vulnerable to Coronavirus disease 2019><vulnerable to SARS-CoV-2><vulnerable to Severe acute respiratory syndrome coronavirus 2>